Antiplatelet agents reduce risk of postoperative IOL bleeding

Article

The use of antiplatelet agents, such as aspirin and clopidogrel, are safer to use compared to anticoagulation (warfarin) therapy, according to the American Journal of Ophthalmology.

The use of antiplatelet agents, such as aspirin and clopidogrel, are safer to use compared to anticoagulation (warfarin) therapy, according to the American Journal of Ophthalmology.

Dr Jaeryung Oh et al., Department of Ophthalmology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, conducted an observational, retrospective case control study on 822 patients who underwent vitreoretinal surgery in 1994, 2004 and 2008.

The outcome measures included the proportion using antiplatelets or anticoagulants, the occurrence of early postoperative intraocular bleeding in patients, and clinical outcomes of the haemorrhage.

The findings demonstrated that the rate of anticoagulant therapy didn't vary and lowers the risk of intraocular haemorrhage after vitrectomy.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.